T2 Biosystems Inc   (TTOO)
Other Ticker:  
Price: $5.4200 $-0.06 -1.095%
Day's High: $5.49 Week Perf: -0.55 %
Day's Low: $ 5.21 30 Day Perf: 41.88 %
Volume (M): 92 52 Wk High: $ 70.00
Volume (M$): $ 501 52 Wk Avg: $20.33
Open: $5.38 52 Wk Low: $3.36

 Market Capitalization (Millions $) 24
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) 11
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

T2 Biosystems Inc
T2 Biosystems Inc is a healthcare company that develops and commercializes innovative diagnostic products for the detection of challenging infectious diseases. Their core technology, called T2 Magnetic Resonance, enables rapid and accurate detection of pathogens and their related biomarkers from various clinical samples. This technology eliminates the need for traditional culture-based methods, which can be time-consuming. T2 Biosystems' products are designed to improve patient outcomes by providing faster and more accurate diagnoses, allowing for more effective treatment decisions.

   Company Address: 101 Hartwell Avenue Lexington 2421 MA
   Company Phone Number: 761-4646   Stock Exchange / Ticker: NASDAQ TTOO
   TTOO is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Financing Agreement

T2 Biosystems: Building a Stronger Future Through Strategic Financial Moves

Published Thu, Feb 15 2024 9:04 PM UTC

T2 Biosystems Strengthens Financial Position and Enhances Shareholder Value with Strategic Moves
In recent news, T2 Biosystems, a leader in rapid detection technology for sepsis-causing pathogens and antibiotic resistance genes, has made two significant strategic moves that are set to benefit the company and its shareholders in the long run.
Firstly, the company ann...


T2 Biosystems Accelerates Global Expansion with Exclusive Distribution Partnerships in Europe and Asia, Strengthening the Fight Against Sepsis

Published Thu, Feb 15 2024 9:02 PM UTC

T2 Biosystems Expands its Presence in Europe and Asia through Distribution PartnershipsLEXINGTON, Mass., Feb. 15, 2024 - T2 Biosystems, a renowned leader in rapid pathogen and antibiotic resistance detection for sepsis, announced today its strategic move towards commercial expansion in Europe and Asia. The company has successfully executed exclusive distribution agreements f...

Product Service News

T2 Biosystems Introduces Enhanced T2Bacteria Panel, Expanding Bacterial Detection Capability to Combat Healthcare-associated Infections

Published Mon, Feb 12 2024 2:00 PM UTC

In a significant move towards revolutionizing the field of diagnostics, T2 Biosystems recently announced receiving FDA 510(k) clearance for the expanded T2Bacteria Panel. This ground-breaking development in microbial detection aims to combat the growing menace of healthcare-associated infections (HAIs) by significantly increasing the number of bacteria species detected. Nota...

Clinical Study

T2 Biosystems Joins Forces with NIH in Groundbreaking Study to Revolutionize Pneumonia Diagnosis

Published Thu, Jan 18 2024 2:00 PM UTC

T2 Biosystems Joins NIH-funded Pilot Study to Revolutionize Pneumonia Detection through Innovative Diagnostic ApproachesLEXINGTON, Mass., Jan. 18, 2024 - T2 Biosystems, Inc. (NASDAQ: TTOO), a prominent leader in rapid detection technology for sepsis-causing pathogens and antibiotic resistance genes, has recently announced its participation in the Antibacterial Resistance Lea...

T2 Biosystems Inc

T2 Biosystems Struggles Amidst Stock Decline and Financial Losses

T2 Biosystems Inc, a leading player in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has been experiencing a tumultuous period recently. With the stock price witnessing a significant decline and reaching its 52-week low, investors are increasingly concerned about the future of the company. However, by analyzing the financial results and recent developments, we can gain insights into how these challenges might impact T2 Biosystems going forward.
1. Stock Decline and Fiscal Performance:
Over the past seven days, T2 Biosystems' stock has plummeted by 18.3%. This decline marks a drastic year-to-date performance of -97.29%. The company's poor financial performance is evident in its fiscal data for the interval closing on September 30, 2023. TTOO reported a loss per share of $-3.45, a significant improvement compared to the previous year's loss of $-295.00 per share. Despite this improvement, the company still faces substantial losses. Additionally, revenue witnessed a sharp decline of -59.967% to $1.47 million, compared to $3.68 million in the same quarter a year before.


T2 Biosystems Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com